Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Food Effect of Mezigdomide in Healthy Adults
NCT04839809Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Jan 2021
- Primary completion
- Oct 2021
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of mezigdomide in multiple myeloma (MM) (2 arms), sponsored by Celgene Corporation. Primary endpoints: Maximum Plasma Concentration, Time to Maximum Plasma Concentration and 8 more. Started Jan 2021; status: completed.
02
Drugs
mezigdomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04839809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04839809.